{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:52:59Z","timestamp":1772743979458,"version":"3.50.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1097\/cco.0b013e32833aaac1","type":"journal-article","created":{"date-parts":[[2010,5,20]],"date-time":"2010-05-20T06:32:19Z","timestamp":1274337139000},"page":"342-346","source":"Crossref","is-referenced-by-count":38,"title":["Trabectedin therapy for sarcomas"],"prefix":"10.1097","volume":"22","author":[{"given":"Paolo G","family":"Casali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Sanfilippo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"D'Incalci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210128","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJMra041866","article-title":"Soft-tissue sarcomas in adults","volume":"353","author":"Clark","year":"2005","journal-title":"N Engl J Med"},{"key":"R2-10-20210128","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1517\/13543784.12.11.1843","article-title":"Preclinical and clinical results with the natural marine product ET-743","volume":"12","author":"D'Incalci","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"R3-10-20210128","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0959-8049(00)00357-9","article-title":"Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action","volume":"37","author":"Erba","year":"2001","journal-title":"Eur J Cancer"},{"key":"R4-10-20210128","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2001.19.5.1248","article-title":"Ecteinascidin-743: a marine derived compound in advanced, pretreated sarcoma patients \u2013 preliminary evidence of activity","volume":"19","author":"Delaloge","year":"2001","journal-title":"J Clin Oncol"},{"key":"R5-10-20210128","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2004.05.210","article-title":"Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients","volume":"22","author":"Yovine","year":"2004","journal-title":"J Clin Oncol"},{"key":"R6-10-20210128","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.2005.01.180","article-title":"Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial","volume":"23","author":"Le Cesne","year":"2005","journal-title":"J Clin Oncol"},{"key":"R7-10-20210128","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2004.02.098","article-title":"Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy","volume":"22","author":"Garcia-Carbonero","year":"2004","journal-title":"J Clin Oncol"},{"key":"R8-10-20210128","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1200\/JCO.2005.05.028","article-title":"Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study","volume":"23","author":"Garcia-Carbonero","year":"2005","journal-title":"J Clin Oncol"},{"key":"R9-10-20210128","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0959-8049(01)00398-7","article-title":"Progression-free rate as the principal endpoint for phase II trials in soft-tissue sarcomas","volume":"38","author":"Van Glabbekea","year":"2002","journal-title":"Eur J Cancer"},{"key":"R10-10-20210128","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","article-title":"Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol"},{"key":"R12-10-20210128","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/jcp.55.5.321","article-title":"Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?","volume":"55","author":"McCluggage","year":"2002","journal-title":"J Clin Pathol"},{"key":"R13-10-20210128","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/CCO.0b013e3281a7ef3a","article-title":"Hormonal therapy of endometrial stromal sarcoma","volume":"19","author":"Reicha","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"R14-10-20210128","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/cncr.2820710440","article-title":"Prognostic factors in early-stage uterine sarcoma: a Gynecologic Oncology Group study","volume":"71","author":"Major","year":"1993","journal-title":"Cancer"},{"key":"R15-10-20210128","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/IGC.0b013e31819c0f59","article-title":"Clinical outcome of ET-743 (trabectedin; yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature","volume":"19","author":"Amant","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"R17-10-20210128","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ygyno.2003.11.023","article-title":"Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study","volume":"92","author":"Look","year":"2004","journal-title":"Gynecol Oncol"},{"key":"R18-10-20210128","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1200\/JCO.2002.11.050","article-title":"Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial","volume":"20","author":"Hensley","year":"2002","journal-title":"J Clin Oncol"},{"key":"R19-10-20210128","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2008.02.024","article-title":"Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R20-10-20210128","first-page":"324","article-title":"Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R21-10-20210128","first-page":"2755","article-title":"Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002","volume":"25","author":"Maki","year":"2007","journal-title":"Clin Oncol"},{"key":"R23-10-20210128","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1470-2045(07)70175-4","article-title":"Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study","volume":"8","author":"Grosso","year":"2007","journal-title":"Lancet Oncol"},{"key":"R24-10-20210128","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/annonc\/mdp004","article-title":"Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series","volume":"20","author":"Grosso","year":"2009","journal-title":"Ann Oncol"},{"key":"R26-10-20210128","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1470-2045(07)70181-X","article-title":"Trabectedin: a targeted chemotherapy?","volume":"8","author":"von Mehren","year":"2007","journal-title":"Lancet Oncol"},{"key":"R27-10-20210128","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1158\/1535-7163.MCT-08-0848","article-title":"Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors","volume":"8","author":"Forni","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"R29-10-20210128","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/91008","article-title":"Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair","volume":"7","author":"Takebayashi","year":"2001","journal-title":"Nat Med"},{"key":"R30-10-20210128","doi-asserted-by":"crossref","first-page":"8155","DOI":"10.1158\/0008-5472.CAN-06-0179","article-title":"Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin","volume":"66","author":"Herrero","year":"2006","journal-title":"Cancer Res"},{"key":"R31-10-20210128","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ejca.2008.01.003","article-title":"Role of homologous recombination in trabectedin-induced DNA damage","volume":"44","author":"Tavecchio","year":"2008","journal-title":"Eur J Cancer"},{"key":"R32-10-20210128","doi-asserted-by":"crossref","first-page":"8231","DOI":"10.1158\/0008-5472.CAN-09-2543","article-title":"A role for BRCA1 in uterine leiomyosarcoma","volume":"69","author":"Xing","year":"2009","journal-title":"Cancer Res"},{"key":"R33-10-20210128","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00280-003-0636-6","article-title":"Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies","volume":"52","author":"Meco","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"R34-10-20210128","first-page":"3251","article-title":"Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells","volume":"7","author":"Takahashi","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R35-10-20210128","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.ejca.2008.11.019","article-title":"Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer","volume":"45","author":"Sessa","year":"2009","journal-title":"Eur J Cancer"},{"key":"R36-10-20210128","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1158\/1078-0432.CCR-08-0336","article-title":"Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma","volume":"14","author":"Blay","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R37-10-20210128","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/annonc\/mdn363","article-title":"A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies","volume":"19","author":"von Mehren","year":"2008","journal-title":"Ann Oncol"},{"key":"R38-10-20210128","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1586\/era.09.28","article-title":"Trabectedin for the management of soft-tissue sarcoma","volume":"9","author":"Boudou","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"R39-10-20210128","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1517\/14656566.9.9.1609","article-title":"Clinical impact of trabectedin (ecteinascidin-743) in advanced\/metastatic soft tissue sarcoma","volume":"9","author":"Sch\u00f6ffski","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"R41-10-20210128","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.ejca.2006.02.010","article-title":"Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma","volume":"42","author":"Grosso","year":"2006","journal-title":"Eur J Cancer"},{"key":"R42-10-20210128","first-page":"5902","article-title":"Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat","volume":"63","author":"Donald","year":"2003","journal-title":"Cancer Res"},{"key":"R43-10-20210128","doi-asserted-by":"crossref","first-page":"7616","DOI":"10.1158\/1078-0432.CCR-09-2127","article-title":"ABCC2, ABCC3, and ABCB1, but not CYP3A, protect against trabectedin-mediated hepatotoxicity","volume":"15","author":"van Waterschoot","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0b013e32833aaac1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:10:44Z","timestamp":1620951044000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201007000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e32833aaac1","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}